CytoSen Therapeutics, Inc. logo

CytoSen Therapeutics, Inc.

CytoSen Therapeutics, Inc. is a biopharmaceutical company bringing innovation to natural killer (NK) cell therapy, merging cellular immunotherapy and nanotechnology to harness the power of the immune system to treat cancer.

Cyto-Sen Therapeutics was created by NK researchers and physicians including UCF researcher Alicja Copik and others at UCF, MD Anderson Cancer Center in Houston and Nationwide Childrens Hospital in Columbus, Ohio.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://cytosen.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1511 E. State Road 434Suite 2001, Room 254 Florida 32708
Winter Springs
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cyto-sen-therapeutics-inc-” connections=”true” suffix=””]

CytoSens PM21 technology develops natural killer cells with its P21 nano particle-based expansion and activation process to produces cellular immunotherapeutics to treat cancers through personalized and universal donor sources. It uses liscenced UCFs technology, which uses nanoparticles to signal and stimulate the NK cells to reproduce nearly 10,000 new cells within 2 weeks from patients single NK cell and arm them to fight against cancer. Pre-clinical results indicate CytoSens PM21 technology in combined delivery treatments may reduce NK cell expansion complexity, expense and timeline while maintaining efficacy.